Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 523

1.

Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification.

Huang SH, O'Sullivan B, Su J, Bartlett E, Kim J, Waldron JN, Ringash J, de Almeida JR, Bratman S, Hansen A, Bayley A, Cho J, Giuliani M, Hope A, Hosni A, Spreafico A, Siu L, Chepeha D, Tong L, Xu W, Yu E.

Radiother Oncol. 2019 Nov 8;144:13-22. doi: 10.1016/j.radonc.2019.10.011. [Epub ahead of print]

PMID:
31710939
2.

OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing.

Malone ER, Saleh RR, Yu C, Ahmed L, Pugh T, Torchia J, Bartlett J, Virtanen C, Hotte SJ, Hilton J, Welch S, Robinson A, McCready E, Lo B, Sadikovic B, Feilotter H, Hanna TP, Kamel-Reid S, Stockley TL, Siu LL, Bedard PL.

Curr Oncol. 2019 Oct;26(5):e618-e623. doi: 10.3747/co.26.5235. Epub 2019 Oct 1.

3.

Characterization and outcomes of patients enrolled to multiple phase I cancer trials.

Kuehne N, Chen L, McDonald K, Wang L, Spreafico A, Hansen A, Razak ARA, Bedard PL, Siu LL, Shepshelovich D.

Cancer Chemother Pharmacol. 2019 Nov 8. doi: 10.1007/s00280-019-03989-x. [Epub ahead of print]

PMID:
31705269
4.

Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma.

Mesia R, Bossi P, Hansen AR, Hsieh CY, Licitra LF, Tan EH, Chen P, Miller J, Siu LL, Haddad RI.

Eur J Cancer. 2019 Nov 4;123:138-145. doi: 10.1016/j.ejca.2019.10.002. [Epub ahead of print]

5.

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.

Heinhuis KM, Carlino M, Joerger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord JP, Paz-Ares L, Britschgi C, Schilder RJ, O'Byrne K, Curigliano G, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Siu LL.

JAMA Oncol. 2019 Nov 7:1-8. doi: 10.1001/jamaoncol.2019.3848. [Epub ahead of print]

PMID:
31697308
6.

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.

Jones RL, Ratain MJ, O'Dwyer PJ, Siu LL, Jassem J, Medioni J, DeJonge M, Rudin C, Sawyer M, Khayat D, Awada A, de Vos-Geelen JMPGM, Evans TRJ, Obel J, Brockstein B, DeGreve J, Baurain JF, Maki R, D'Adamo D, Dickson M, Undevia S, Geary D, Janisch L, Bedard PL, Abdul Razak AR, Kristeleit R, Vitfell-Rasmussen J, Walters I, Kaye SB, Schwartz G.

Eur J Cancer. 2019 Oct;120:132-139. doi: 10.1016/j.ejca.2019.07.024. Epub 2019 Sep 12.

7.

Clinical Utility of Cytokine Biomarker Analysis of Pancreatic Cyst Fluid Obtained by Endoscopic Ultrasound Fine Needle Aspiration: A Pilot Study.

Siu L, Paredes J, Kurbatov V, Ramachandran R, Serafini F, Grossman E, Gress F, Martello L.

Pancreas. 2019 Sep;48(8):e60-e61. doi: 10.1097/MPA.0000000000001365. No abstract available.

PMID:
31425485
8.

Resistance mechanisms and molecular epidemiology of carbapenem-nonsusceptible Escherichia coli in Taiwan, 2012-2015.

Chang YT, Siu LK, Wang JT, Wu TL, Chen YH, Chuang YC, Lin JC, Lu PL.

Infect Drug Resist. 2019 Jul 16;12:2113-2123. doi: 10.2147/IDR.S208231. eCollection 2019.

9.

Domain 4 of pneumolysin from Streptococcus pneumoniae is a multifunctional domain contributing TLR4 activating and hemolytic activity.

Chiu FF, Leng CH, Ding YJ, Chang JC, Chang LS, Lien SP, Chen HW, Siu LK, Liu SJ.

Biochem Biophys Res Commun. 2019 Oct 1;517(4):596-602. doi: 10.1016/j.bbrc.2019.07.063. Epub 2019 Aug 5.

10.

How liquid biopsies can change clinical practice in oncology.

Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A.

Ann Oncol. 2019 Oct 1;30(10):1580-1590. doi: 10.1093/annonc/mdz227.

PMID:
31373349
11.

Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.

Oliva M, Huang SH, Xu W, Su J, Hansen AR, Bratman SV, Ringash J, Jang R, Cho J, Bayley A, Hope AJ, Chen E, Giuliani M, Waldron J, Weinreb I, Perez-Ordonez B, Chepeha D, Kim J, O Sullivan B, Siu LL, Spreafico A.

Eur J Cancer. 2019 Sep;118:112-120. doi: 10.1016/j.ejca.2019.06.019. Epub 2019 Jul 19.

PMID:
31330486
12.

Utilization of tumor genomics in clinical practice: an international survey among ASCO members.

Barroso-Sousa R, Guo H, Srivastava P, James T, Birch W, Siu LL, Tew WP, Tolaney SM.

Future Oncol. 2019 Jul;15(21):2463-2470. doi: 10.2217/fon-2019-0010. Epub 2019 Jun 26.

PMID:
31238721
13.

Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials.

Gadalla R, Noamani B, MacLeod BL, Dickson RJ, Guo M, Xu W, Lukhele S, Elsaesser HJ, Razak ARA, Hirano N, McGaha TL, Wang B, Butler M, Guidos CJ, Ohashi PS, Siu LL, Brooks DG.

Front Oncol. 2019 May 17;9:415. doi: 10.3389/fonc.2019.00415. eCollection 2019.

14.

Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion.

Adelstein DJ, Ismaila N, Ku JA, Burtness B, Swiecicki PL, Mell L, Beitler JJ, Gross N, Jones CU, Kaufman M, Le QT, Semrad TJ, Siu LL, Ridge JA.

J Clin Oncol. 2019 Jun 20;37(18):1578-1589. doi: 10.1200/JCO.19.00441. Epub 2019 Apr 25.

PMID:
31021656
15.

Designing circulating tumor DNA-based interventional clinical trials in oncology.

Araujo DV, Bratman SV, Siu LL.

Genome Med. 2019 Apr 19;11(1):22. doi: 10.1186/s13073-019-0634-x.

16.

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

Hellmann MD, Kim TW, Lee CB, Goh BC, Miller WH, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang YJ, Siu LL, Bendell J.

Ann Oncol. 2019 Jul 1;30(7):1134-1142. doi: 10.1093/annonc/mdz113.

PMID:
30918950
17.

Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy.

Le QT, Colevas AD, O'Sullivan B, Lee AWM, Lee N, Ma B, Siu LL, Waldron J, Lim CM, Riaz N, Lynn J, Malik S.

J Natl Cancer Inst. 2019 Mar 26. pii: djz044. doi: 10.1093/jnci/djz044. [Epub ahead of print]

PMID:
30912808
18.

Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations.

Leung GMK, Zhang C, Ng NKL, Yang N, Lam SSY, Au CH, Chan TL, Ma ESK, Tsui SP, Ip HW, So JCC, Ng MHL, Cheng KCK, Wong KF, Siu LLP, Yip SF, Lin SY, Lau JSM, Luk TH, Lee HKK, Lau CK, Kho B, Kwong YL, Leung AYH.

Am J Hematol. 2019 Jun;94(6):650-657. doi: 10.1002/ajh.25469. Epub 2019 Apr 16.

PMID:
30900772
19.

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL.

J Immunother Cancer. 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0.

20.

Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era.

Tan T, Rheaume M, Wang L, Chow H, Spreafico A, Hansen AR, Razak ARA, Siu LL, Bedard PL.

Oncologist. 2019 Jul;24(7):e518-e525. doi: 10.1634/theoncologist.2018-0808. Epub 2019 Mar 4.

PMID:
30833487
21.

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani NC, Mackay H, Butler MO, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard PL, Oza AM.

Gynecol Oncol. 2019 May;153(2):304-311. doi: 10.1016/j.ygyno.2019.02.005. Epub 2019 Feb 18.

PMID:
30792002
22.

Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.

Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, Siu LL, Hansen A, Razak AA, Spreafico A, Leighl N, Joshua AM, Butler MO, Hogg D, Chappell MA, Soultani L, Chow K, Boujos S, Bedard PL.

Cancer. 2019 Apr 15;125(8):1341-1349. doi: 10.1002/cncr.31999. Epub 2019 Feb 15.

PMID:
30768786
23.

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.

de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ, Abdul Razak AR, De Vos FYFL, Verheijen RB, Schnell D, Pronk LC, Jansen M, Siu LL.

Target Oncol. 2019 Feb;14(1):43-55. doi: 10.1007/s11523-018-00617-1.

24.

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.

Verheijen RB, van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, de Jonge MJA, Pronk LC, De Vos FYFL, Schnell D, Hirte HW, Steeghs N, Lolkema MP.

Target Oncol. 2019 Feb;14(1):67-74. doi: 10.1007/s11523-018-00618-0.

25.

Appropriate Treatment for Bloodstream Infections Due to Carbapenem-Resistant Klebsiella pneumoniae and Escherichia coli: A Nationwide Multicenter Study in Taiwan.

Lin YT, Su CF, Chuang C, Lin JC, Lu PL, Huang CT, Wang JT, Chuang YC, Siu LK, Fung CP.

Open Forum Infect Dis. 2018 Dec 17;6(2):ofy336. doi: 10.1093/ofid/ofy336. eCollection 2019 Feb.

26.

Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.

Shepshelovich D, McDonald K, Spreafico A, Razak ARA, Bedard PL, Siu LL, Minasian L, Hansen AR.

Oncologist. 2019 Apr;24(4):e146-e148. doi: 10.1634/theoncologist.2018-0332. Epub 2019 Feb 6.

PMID:
30728278
27.

TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses.

Mandilaras V, Garg S, Cabanero M, Tan Q, Pastrello C, Burnier J, Karakasis K, Wang L, Dhani NC, Butler MO, Bedard PL, Siu LL, Clarke B, Shaw PA, Stockley T, Jurisica I, Oza AM, Lheureux S.

Int J Gynecol Cancer. 2019 Jan 18. pii: ijgc-2018-000087. doi: 10.1136/ijgc-2018-000087. [Epub ahead of print]

PMID:
30659026
28.

Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response.

Sud S, O'Callaghan C, Jonker C, Karapetis C, Price T, Tebbutt N, Shapiro J, Van Hazel G, Pavlakis N, Gibbs P, Jeffrey M, Siu L, Gill S, Wong R, Jonker D, Tu D, Goodwin R.

Curr Oncol. 2018 Dec;25(6):e516-e526. doi: 10.3747/co.25.4069. Epub 2018 Dec 1.

29.

Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20.

Wells JC, Tu D, Siu LL, Shapiro JD, Jonker DJ, Karapetis C, Simes J, Liu G, Price TJ, Tebbutt NC, O'Callaghan CJ.

Clin Colorectal Cancer. 2019 Mar;18(1):e140-e149. doi: 10.1016/j.clcc.2018.11.006. Epub 2018 Nov 28.

PMID:
30595557
30.

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R.

Eur J Cancer. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18.

31.

Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels.

Sukhai MA, Misyura M, Thomas M, Garg S, Zhang T, Stickle N, Virtanen C, Bedard PL, Siu LL, Smets T, Thijs G, Van Vooren S, Kamel-Reid S, Stockley TL.

J Mol Diagn. 2019 Mar;21(2):261-273. doi: 10.1016/j.jmoldx.2018.09.008. Epub 2018 Dec 19.

PMID:
30576869
32.

Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.

Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL.

J Natl Cancer Inst. 2019 Feb 1;111(2):118-128. doi: 10.1093/jnci/djy196.

33.

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.

Kanjanapan Y, Day D, Butler MO, Wang L, Joshua AM, Hogg D, Leighl NB, Razak ARA, Hansen AR, Boujos S, Chappell M, Chow K, Sherwin B, Stayner LA, Soultani L, Zambrana A, Siu LL, Bedard PL, Spreafico A.

Eur J Cancer. 2019 Jan;107:1-7. doi: 10.1016/j.ejca.2018.10.017. Epub 2018 Dec 7.

PMID:
30529898
34.

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma.

Oliva M, Spreafico A, Taberna M, Alemany L, Coburn B, Mesia R, Siu LL.

Ann Oncol. 2019 Jan 1;30(1):57-67. doi: 10.1093/annonc/mdy507.

35.

Klebsiella pneumoniae disassembles host microtubules in lung epithelial cells.

Chua MD, Liou CH, Bogdan AC, Law HT, Yeh KM, Lin JC, Siu LK, Guttman JA.

Cell Microbiol. 2019 Mar;21(3):e12977. doi: 10.1111/cmi.12977. Epub 2018 Nov 22.

PMID:
30415487
36.

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J.

JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628.

37.

Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.

Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G.

Cancer Med. 2018 Nov;7(11):5478-5487. doi: 10.1002/cam4.1819. Epub 2018 Oct 14.

38.

When Community Calls, We Collaborate! Community-Based Participatory Research With the Multilanguage Montagnard Refugee Community.

Morrison SD, Sudha S, Young A, Dharod J, Nie YB, Siu HW, Siu L, Ksor HV, Sayers J, Bernot K, Malotky M, Nsonwu M.

Prog Community Health Partnersh. 2018;12(2):179-186. doi: 10.1353/cpr.2018.0038.

PMID:
30270228
39.

Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.

Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies.

Ann Oncol. 2018 Nov 1;29(11):2175-2182. doi: 10.1093/annonc/mdy398. Review.

PMID:
30202892
40.

Additional germline findings from a tumor profiling program.

Stjepanovic N, Stockley TL, Bedard PL, McCuaig JM, Aronson M, Holter S, Semotiuk K, Leighl NB, Jang R, Krzyzanowska MK, Oza AM, Gupta A, Elser C, Ahmed L, Wang L, Kamel-Reid S, Siu LL, Kim RH.

BMC Med Genomics. 2018 Aug 9;11(1):65. doi: 10.1186/s12920-018-0383-5.

41.

Precision Medicine in Head and Neck Cancer: Myth or Reality?

Malone E, Siu LL.

Clin Med Insights Oncol. 2018 Jun 4;12:1179554918779581. doi: 10.1177/1179554918779581. eCollection 2018.

42.

Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma-Exploration for Achieving Optimal 10-Year Therapeutic Ratio.

Ng WT, Tung SY, Lee V, Ngan RKC, Choi HCW, Chan LLK, Leung TW, Siu LL, Lu TX, Tan T, Tan EH, Sze HCK, Ng AWY, Yiu HHY, O'Sullivan B, Chappell R, Lee AWM.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1078-1086. doi: 10.1016/j.ijrobp.2018.04.069. Epub 2018 May 2.

PMID:
29885997
43.

Lung cancer in never smokers from the Princess Margaret Cancer Centre.

Korpanty GJ, Kamel-Reid S, Pintilie M, Hwang DM, Zer A, Liu G, Leighl NB, Feld R, Siu LL, Bedard PL, Tsao MS, Shepherd FA.

Oncotarget. 2018 Apr 27;9(32):22559-22570. doi: 10.18632/oncotarget.25176. eCollection 2018 Apr 27.

44.

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C.

J Clin Oncol. 2018 Oct 20;36(30):3007-3014. doi: 10.1200/JCO.2018.78.2292. Epub 2018 May 7.

PMID:
29733771
45.

Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort.

Bernstein LJ, Pond GR, Gan HK, Tirona K, Chan KK, Hope A, Kim J, Chen EX, Siu LL, Razak ARA.

Head Neck. 2018 Sep;40(9):2029-2042. doi: 10.1002/hed.25198. Epub 2018 Apr 17.

PMID:
29667262
46.

Rational design and identification of immuno-oncology drug combinations.

Iafolla MAJ, Selby H, Warner K, Ohashi PS, Haibe-Kains B, Siu LL.

Eur J Cancer. 2018 May;95:38-51. doi: 10.1016/j.ejca.2018.02.027. Epub 2018 Apr 7. Review.

PMID:
29631102
47.

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.

Aghajanian C, Bell-McGuinn KM, Burris HA 3rd, Siu LL, Stayner LA, Wheler JJ, Hong DS, Kurkjian C, Pant S, Santiago-Walker A, Gauvin JL, Antal JM, Opalinska JB, Morris SR, Infante JR.

Invest New Drugs. 2018 Dec;36(6):1016-1025. doi: 10.1007/s10637-018-0591-z. Epub 2018 Apr 3.

PMID:
29611022
48.

Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement Summary.

Nekhlyudov L, Lacchetti C, Siu LL.

J Oncol Pract. 2018 Mar;14(3):167-171. doi: 10.1200/JOP.2017.029041. Epub 2017 Dec 19. No abstract available.

PMID:
29257719
49.

Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan.

Su CF, Chuang C, Lin YT, Chan YJ, Lin JC, Lu PL, Huang CT, Wang JT, Chuang YC, Siu LK, Fung CP.

Eur J Clin Microbiol Infect Dis. 2018 Apr;37(4):651-659. doi: 10.1007/s10096-017-3156-8. Epub 2017 Dec 14.

PMID:
29238934
50.

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.

Pezo RC, Chen TW, Berman HK, Mulligan AM, Razak AA, Siu LL, Cescon DW, Amir E, Elser C, Warr DG, Sridhar SS, Yu C, Wang L, Stockley TL, Kamel-Reid S, Bedard PL.

Breast Cancer Res Treat. 2018 Feb;168(1):159-168. doi: 10.1007/s10549-017-4580-2. Epub 2017 Nov 24.

Supplemental Content

Support Center